Download Champions' latest AACR 2024 Poster

Champions’ TumorGraft3D (CTG3D) platform generates robust preclinical models, efficiently mimicking cancer organoid and immune cell interactions. Using traceable tags (e.g., bioluminescent and fluorescent), it enables rapid, cost-effective testing of multiple agents. Our stable Luc and GFP-tagged CTG3D-immune co-culture platform supports various cancer types (colon, prostate, gastric, non-small cell lung cancer, leukemia) with autologous TILs, allogenic TILs, and expanded NK cells.

• The bioluminescent 3D immune organoid co-culture allows faster screening of novel agents by using PDX and PDXO models with diverse genetic backgrounds to assess drug performance in tumor-specific immune environments.

• The bioluminescent CTG3D-immune co-culture platform offers a faster, cost-effective way to optimize the E:T ratio and evaluate IO drug performance with advanced endpoints.

• Bioluminescent PDX and PDXO cells provide new options for evaluating therapeutic efficacy and monitoring tumor metastasis via in vivo imaging.